

**Kin Wei (Arnold) Chan, MD, ScD**

Senior Scientist, i3 Drug Safety

Arnold Chan directs i3 Aperio®, which tracks newly approved prescription drugs in real-world use to provide stakeholders information on potential safety issues. In that role, he provides medical insight and oversees i3's research and the reports generated. Dr. Chan is a pharmacoepidemiologist whose research has focused on studying drug, device and vaccine safety, and utilization and efficacy through large, linked automated health care databases. Prior to joining i3 Drug Safety, he was director of the pharmacoepidemiology program at the Harvard School of Public Health and an associate professor in the Department of Epidemiology. He served as assistant director of epidemiology and statistics at Ciba-Geigy Corporation and on several committees at the National Institutes of Health, the International Society for Pharmacoepidemiology, and the Bureau of Pharmaceutical Affairs in Taiwan's Department of Health. Dr. Chan was elected Fellow of the International Society of Pharmacoepidemiology in 2003 and has received numerous international honors for his work; more than 60 of his articles have been published in peer reviewed journals.

**Terri Madison, PhD, MPH**

President, i3 Drug Safety

Terri Madison, PhD, MPH, is President of i3 Drug Safety, whose mission is to advance health through research and services that focus on the safety of drugs, devices, and biologics. In that role, her responsibilities include business and scientific leadership for safety services provided by the regulatory drug safety and epidemiology teams. Dr. Madison is a proven leader in the i3 organization, where she most recently served as Sr. Vice President of Global Operations at i3 Statprobe, a sister company within i3 focused on providing data services support. Terri received her doctorate in epidemiology from the University of Michigan, and a MPH from the University of Michigan School of Public Health. Terri has 20 years of industry experience, including positions at Parke-Davis Pharmaceutical Research and STATPROBE prior to joining i3. In addition to her substantial experience in data collection, analysis and reporting across multiple therapeutic areas within the biopharmaceutical and biotechnology industry, Terri's research includes the design, conduct, and analysis of observational cancer studies, where she has worked with both state and national cancer registries to evaluate factors associated with prognosis.